Ipamorelin + Sermorelin for Women: What the Research Covers, and What It Leaves Out

This is the most detailed adult trial in the sermorelin literature and the only one in the live research that reported women and men separately. Ten women and nine men aged 55 to 71 self-injected placebo nightly for four weeks, then a norleucine-substituted GHRH(1-29) analogue, a closely related molecule, nightly for sixteen weeks (Journal of Clinical Endocrinology and Metabolism).

The only adverse effect recorded was a transient lipid rise.

What it shows. A GHRH analogue prompts the growth hormone axis in older women as well as men, and skin thickness changed in both.

What it does not show. That lean mass or insulin sensitivity change in women; in this trial they did not. Nineteen people is a small trial, nobody has followed up the sex difference, and nothing measured how skin looked.

The human pharmacology for ipamorelin is a 1999 intravenous dose-escalation study in healthy male volunteers, which reported a single growth hormone pulse per dose peaking at about 40 minutes. The one randomised trial, of intravenous ipamorelin after bowel surgery in 114 adults, did not meet its endpoint and was not about anything women take it for today. There is no human study of ipamorelin reporting results in women, and nothing on the subcutaneous route at all.

The growth hormone axis does not respond identically in women. That is a reason not to assume results reported mainly in men apply to women, and one reason a physician may weigh the paired vial against sermorelin alone, CJC-1295 / Ipamorelin, or a sleep-focused option, depending on what you want help with.

The largest natural growth hormone pulse of the day arrives in slow-wave sleep, and a 2000 paper in JAMA described the two declining together across adult life, in healthy men. The paired vial is dosed at bedtime to add to that pulse. That is the mechanistic rationale, not a trial result: a 2003 review in Endocrine notes that a short-acting GHRH did not improve measured sleep under trial conditions, and sleep quality was unchanged in the 1997 trial. Many people describe sleep feeling deeper; that is a report, not a demonstrated outcome.

Waking in the early hours is common in perimenopause and after. Night sweats wake people directly, falling progesterone removes a mildly sedating hormone, slow-wave sleep declines with age, and sleep apnea becomes more common after menopause and can present as insomnia rather than snoring. Which of those is driving the waking decides whether a peptide is even the right category of answer. If night sweats are the cause, that is a hormone conversation, and Pepti does not prescribe menopausal hormone therapy.

It does not treat hot flashes, night sweats, genitourinary symptoms or bone loss, and it does not replace estrogen. More in peptides for menopause and peptides for women. If sleep is the whole point, DSIP is aimed at it more directly; see peptides for sleep.

Ipamorelin + Sermorelin is not used in pregnancy or breastfeeding: there is no safety data for either component, the trials excluded these groups, and there is no clinical reason to accept the uncertainty. If you become pregnant on treatment, stop and contact your physician the same day. See can you take peptides while pregnant.

No human fertility outcome data exists for either component. Growth hormone and IGF-1 signalling interact with reproductive endocrinology, which is a reason for caution rather than a measured effect in either direction. Tell your physician if you are trying. See do peptides affect fertility.

Both peptides raise your own growth hormone and IGF-1. No study has shown that either causes cancer, though long-term cancer-incidence data for the class do not exist. A 2004 systematic review in the Lancet reported that higher circulating IGF-1 in the general population was associated with a higher risk of premenopausal breast cancer, among others; that is an observational association, not evidence about a monitored medication. A history of breast, ovarian or endometrial cancer is a conversation with your physician, and often your oncologist, before anything starts.

Growth hormone reduces insulin sensitivity. Fasting glucose was unchanged in the published sermorelin trials, but insulin sensitivity tends to worsen through the menopausal transition anyway, so diabetes or impaired glucose tolerance needs discussing at intake.

Ipamorelin acts at the receptor ghrelin, the hunger hormone, uses, and some people report more appetite after the dose. Sermorelin alone is not usually associated with appetite change. Report it if it matters for your goals.

Neither peptide acts on the ovarian axis, and no trial has looked at cycle effects. Report any cycle change; it is more likely to be the transition than the peptide, but it should be looked at. No interaction with hormone therapy or contraception has been described, and none has been studied, so list both on your intake.